KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Asset Writedowns and Impairment (2016 - 2025)

West Pharmaceutical Services' Asset Writedowns and Impairment history spans 8 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 35.19% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $11.7 million, up 60.27%, while the annual FY2025 figure was $11.7 million, 60.27% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $7.3 million at West Pharmaceutical Services, up from $300000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $7.3 million in Q4 2025 and bottomed at $200000.0 in Q2 2022.
  • The 4-year median for Asset Writedowns and Impairment is $1.5 million (2023), against an average of $2.3 million.
  • The largest annual shift saw Asset Writedowns and Impairment tumbled 80.0% in 2024 before it surged 1166.67% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $4.6 million in 2022, then plummeted by 41.3% to $2.7 million in 2023, then skyrocketed by 100.0% to $5.4 million in 2024, then surged by 35.19% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Asset Writedowns and Impairment are $7.3 million (Q4 2025), $300000.0 (Q3 2025), and $3.8 million (Q2 2025).